A Retrospective Analysis Of Two Neoadjuvant Chemotherapy Regimens For The Treatment Of Cervical Cancer

Objective: To explore the effect and toxicity of paclitaxel liposome combined with nedaplatin and docetaxel combined with nedaplatin in the neoadjuvant chemotherapy of cervical cancer, and evaluate the advantages and disadvantages of the two kinds of neoadjuvant chemotherapy for providing evidence of evidence-based medicine to seek for the optimum of cervical cancer neoadjuvant chemotherapy.Methods: Patients of the gynecology department of the First Hospital Affiliated to Nanhua University in July 2011 to July 2015 from cervical cancer were selected for neoadjuvant chemotherapy of cancer patients, according to the FIGO staging method, treatment plan according to the wishes of patients assigned. The experimental group was divided into control group(docetaxel combined with nedaplatin) with 48 cases and experimental group(paclitaxel liposome combined with nedaplatin) with 48 cases, treatment for interventional chemotherapy intravenous chemotherapy combined with nedaplatin in uterine artery, finally after surgery, to determine whether the need for radiotherapy according to intraoperative and pathological results. Through the observation before and after chemotherapy and uterine cervical tumor size changes and postoperative disease check for cervical cancer compared the two kinds of neoadjuvant chemotherapy efficacy, and observed the side effects of chemotherapy in two group patients. The data collected for statistical analysis method, the comparative evaluation of two different neoadjuvant chemotherapy regimen in the treatment of cervical cancer was practised.Results: 1) In investigation of paclitaxel liposome combined with nedaplatin and docetaxel combined with nedaplatin on recent local curative effect of neoadjuvant chemotherapy for cervical cancer, clinical analysis showed that the total effective rate of the both treatment or clinical benefit rate, there was no significant difference between two groups(P > 0.05).2) On paclitaxel liposome combination of nedaplatin and docetaxel combined with nedaplatin on postoperative cervical carcinoma after chemotherapy, the pathological results of pathological results showed that both the primary lesions in cervical cancer residue, uterine body, double accessories and parametrial infiltration, vaginal stump positive margin, or lymph node metastasis rate, there was no significant difference between the two groups(P > 0.05).3) Of paclitaxel liposome combined with nedaplatin and docetaxel combined with nedaplatin on toxicity of neoadjuvant chemotherapy for cervical cancer, the results showed that in the experimental group(P= 0.003), nausea and vomiting(P=0.050) and muscle soreness(P = 0.027) and incidences of allergic reaction(P = 0.045) rate was significantly better than the control group. But in the cause of diarrhea(P = 0.330), abdominal pain(P = 0.300) and peripheral neurotoxicity(P = 0.078), oral ulcer(P = 0.092) and alopecia masses(P = O. 423), the differences was no statistical significance between the two groups.Conclusion:(1) The paclitaxel liposome combined with nedaplatin platinum and docetaxel combined with nedaplatin platinum of neoadjuvant chemotherapy for cervical cancer was no significant difference in efficacy.(2) Adverse reaction rate of paclitaxel liposome combined with nedaplatin regimen was significantly less than that of docetaxel combined with nedaplatin, and relatively more safety.